Abstracts tagged "anakinra and familial Mediterranean fever"

Abstract Number: 246 • 2016 ACR/ARHP Annual Meeting
Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis
Bahtiyar Toz¹, Seher Tecer², Emin Oğuz¹, Murat Erdugan¹, Bahar Artim-Esen¹, Sevil Kamali³, Murat Inanc⁴, Lale Ocal³, Burak Erer¹ and Ahmet Gul¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Istanbul faculty of medicine Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF), the most common form of hereditary autoinflammatory diseases, is associated with increased risk for secondary (AA) amyloidosis. We herein aimed…
Abstract Number: 943 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever Who Underwent Kidney Transplantation
Bahtiyar Toz¹, Yaşar Kerem Çalışkan², Burak Erer¹, Lale Ocal³ and Ahmet Gul¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Nephrology, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey, ³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by self-limiting febrile attacks associated with serosal or synovial inflammation as well as increased…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].